investigating In vivo Bioequivalence of Adult Cold Tablet

In vivo Bioequivalence Study of Adult Cold Tablet Based on 15 mg Dextrometorphane manufactured by Chemidarou compared to innovator product

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220211053992N2

Enrollment

Registered

2022-06-06

Start date

2022-05-31

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In the present study, no diseases will be examined and products will be administered by healthy volunteers..

Interventions

Intervention 1: Intervention group: Healthy volunteers in Intervention group will receive only two test drug product (Adult cold tablet manufactured by Chemidarou Co. containing 15 mg Dextromethorphan

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: General Health (Liver, Heart and Kidney) Age between 18 to 59 years

Exclusion criteria

Exclusion criteria: Smoking History of cardiovascular disease, liver and kidney disease Pregnancy Alcohol and drug addiction History of drug allergy

Design outcomes

Primary

Measure	Time frame
Plasma Drug Concentration. Timepoint: 0.5-24 hours in predetermined time intervals after drug administration. Method of measurement: HPLC (High performance liquid chromatography).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHadi Valizadeh

Tabriz University of Medical Sciences

valizadehh@gmail.com+98 41 3334 8801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026